 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology, Inc. (Vir or the Company, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the Board) at its upcoming...

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company...

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024

Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR  Get Free Report) CFO Sung Lee sold 6,008 shares of Vir Biotechnology stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at...

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Sung Lee Sells 6,008 Shares of Stock

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results PR Newswire DURHAM...

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Investors considering a purchase of Vir Biotechnology Inc (VIR) shares, but cautious about paying the going market price of 10.69/share, might benefit from considering selling puts among the...

Commit To Purchase Vir Biotechnology At $7.50, Earn 8.9% Annualized Using Options

This indicator may be signaling that VIR's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Vir Biotechnology (VIR, $11.38) entered Downtrend as Momentum indicator drops below 0 level on Mar 08, 2024

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people...

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Vir Biotechnology (NASDAQ:VIR  Get Free Report) and Compugen (NASDAQ:CGEN  Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the...

Comparing Vir Biotechnology (NASDAQ:VIR) & Compugen (NASDAQ:CGEN)

Vir Biotechnology, Inc. (NASDAQ:VIR  Get Free Report)s share price fell 2.7% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $11.42 and...

Vir Biotechnology (NASDAQ:VIR) Trading Down 2.7% on Insider Selling

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Volume (M)	1.08M
52-Wk High	$27.48
52-Wk Low	$7.72

VIR Vir Biotechnology Inc

About

Feed

News

Sentiment

Earnings

Fundamentals